Peptide-Drug Conjugates represent an emerging class of targeted therapeutics that combine the specificity of peptides with the potency of cytotoxic drugs.
PDC Architecture
Three Components 1. **Homing Peptide** — Binds overexpressed receptor 2. **Linker** — Controls drug release 3. **Payload** — Cytotoxic or therapeutic agent
Mechanism of Action 1. PDC binds to receptor on target cell 2. Receptor-mediated endocytosis 3. Linker cleavage releases payload 4. Cytotoxic effect kills cell
Comparison with Other Platforms
| Feature | Small Molecules | PDCs | ADCs |
|---|---|---|---|
| Size | <500 Da | 2-10 kDa | ~150 kDa |
| Tumor penetration | Excellent | Good | Poor |
| Specificity | Low-moderate | High | Very high |
| Manufacturing | Simple | Moderate | Complex |
| Cost | Low | Moderate | High |
| Immunogenicity | None | Low | Moderate |
Targeting Peptides
Receptor Targets - **Somatostatin receptors** — Overexpressed in NET - **GnRH receptors** — Prostate, breast cancer - **Integrin αvβ3** — Tumor vasculature - **Bombesin receptors** — Prostate, breast cancer - **CXCR4** — Many solid tumors
Example Peptides | Peptide | Target | Application | |---------|--------|-------------| | Octreotide | SSTR | Neuroendocrine tumors | | RGD peptides | Integrins | Anti-angiogenic | | Bombesin | GRPR | Prostate cancer | | Substance P | NK1R | Various tumors |
Linker Chemistry
Cleavable Linkers - **Enzyme-sensitive** — Cathepsin B (Val-Cit-PABC) - **pH-sensitive** — Hydrazone (acid-labile) - **Redox-sensitive** — Disulfide bonds
Non-Cleavable Linkers - Payload released after peptide degradation - More stable in circulation - Requires complete lysosomal processing
Payloads
Cytotoxic Agents - **Auristatins** — Microtubule inhibitors - **Maytansinoids** — Microtubule inhibitors - **Doxorubicin** — DNA intercalator - **SN-38** — Topoisomerase inhibitor
Radioisotopes (for PRRT) - **Lutetium-177** — β-emitter - **Yttrium-90** — β-emitter - **Actinium-225** — α-emitter
Peptide Receptor Radionuclide Therapy (PRRT)
A successful PDC application for neuroendocrine tumors:
- Octreotide analog conjugated to DOTA chelator
- Labeled with Lutetium-177
- FDA-approved for gastroenteropancreatic NET
- Delivers targeted radiation to SSTR-positive cells